What are the recommended antibiotics for community-acquired pneumonia (CAP)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Article Review Status
Submitted
Under Review
Approved

Last updated: February 14, 2025 • View editorial policy

From the Guidelines

Community-acquired pneumonia (CAP) treatment should start with antibiotics that cover common bacterial pathogens, such as Streptococcus pneumoniae, Haemophilus influenzae, and atypical pathogens like Legionella species.

  • For healthy adults, recommended options include amoxicillin, doxycycline, or a macrolide (e.g., azithromycin, clarithromycin) 1, 2.
  • For patients with comorbidities, a β-lactam with a macrolide or a respiratory fluoroquinolone is recommended 1, 2.
  • The choice of antibiotic should be based on effective treatment of the most commonly reported bacterial pathogens and may include an aminopenicillin with clavulanic acid, a macrolide, or a tetracycline 1.

Duration of Antibiotic Therapy

  • Antibiotics for CAP should be prescribed for a minimum of 5 days 1, 3.
  • Extension of therapy after 5 days of antibiotics should be guided by validated measures of clinical stability, which include resolution of vital sign abnormalities, ability to eat, and normal mentation 1, 3.

Special Considerations

  • For patients with suspected aspiration with infection, amoxicillin-clavulanate or clindamycin is recommended 2.
  • For patients with influenza and bacterial superinfection, a β-lactam or a respiratory fluoroquinolone is recommended 2.
  • In patients with CAP and COVID-19, empirical coverage for bacterial pathogens is recommended, but not required in all patients with confirmed COVID-19–related pneumonia 4.

From the Research

The following antibiotics have been recommended or are being developed for the treatment of CAP:

  • Delafloxacin
  • Omadacycline
  • Lefamulin
  • Solithromycin
  • Nemonoxacin
  • Ceftaroline 5 These antibiotics have activity against methicillin-resistant Staphylococcus aureus and macrolide-resistant Streptococcus pneumoniae.

Narrow-Spectrum Antibiotics

Narrow-spectrum antibiotics, such as macrolides and doxycycline, are recommended for the treatment of CAP in otherwise healthy adults 6, 7.

  • Macrolide monotherapy is associated with a lower risk of adverse drug events (ADEs) compared to broad-spectrum antibiotics 6.
  • Doxycycline is also a narrow-spectrum antibiotic that can be used to treat CAP 6, 7.

Broad-Spectrum Antibiotics

Broad-spectrum antibiotics, such as fluoroquinolones and β-lactams, are associated with an increased risk of ADEs 6.

  • Fluoroquinolones are broad-spectrum antibiotics that can be used to treat CAP, but they are associated with an increased risk of ADEs 6.
  • β-lactams are also broad-spectrum antibiotics that can be used to treat CAP, but they are associated with an increased risk of ADEs 6.

Current Treatment Guidelines

Current treatment guidelines for CAP recommend risk stratification of patients by severity and proper place of therapy 7.

  • Effective management of CAP requires additional therapeutic interventions along with antibiotics, especially in severe CAP 7.
  • New antibiotics and adjunctive therapies, such as corticoids, have recently been tested for the treatment of CAP 7, 8.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.